Announcements Trials
Browse Landscape Eligibility

Clinical Trials

4 trials
RecentStart dateEnrollment
CYH33 × Clear all

Phase

Phase 1 3Phase 2 1

Status

Unknown 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Breast 2Other solid neoplasm 1Genitourinary 1

Conditions

Ovarian Neoplasms 2Recurrence 1Prostatic Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1Advanced Breast Cancer 1

Interventions

Cisplatin 3176Cyclophosphamide 3172Carboplatin 2955Radiotherapy 2771Paclitaxel 2705Gemcitabine 2549pembrolizumab 2368Bevacizumab 2192Docetaxel 2190Fluorouracil 1837Capecitabine 1815Oxaliplatin 1723Dexamethasone 1592Nivolumab 1575Doxorubicin 1500Rituximab 1480Magnetic Resonance Spectroscopy 1365Etoposide 1341Irinotecan 1240Leucovorin 1215Drug Therapy 1189Cytarabine 1126Pemetrexed 1067fludarabine 1035Specimen Handling 985Vincristine 964Prednisone 940Cetuximab 938Trastuzumab 936Lenalidomide 932

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT05043922 2026-01-30

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Haihe Biopharma Co., Ltd.

Phase 2 Active not recruiting
93 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03544905 2025-04-22

Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33

Haihe Biopharma Co., Ltd.

Phase 1 Completed
206 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Haihe Biopharma Co., Ltd.

Phase 1 Terminated
24 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT04856371 2021-04-23

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Haihe Biopharma Co., Ltd.

Phase 1 Unknown
228 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡